Both FK866 and CQ-85, an in vivo-feasible PD-L1 inhibitor, effectively inhibited tumor growth in mice at the same dose (20 mg/kg), whereas combined treatment with both inhibitors showed a stronger antitumor effect (Fig. 6A,B; Appendix Fig. S5B,C). Here, CD274 is linked to neoplasm.